MX2017007097A - Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma). - Google Patents
Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).Info
- Publication number
- MX2017007097A MX2017007097A MX2017007097A MX2017007097A MX2017007097A MX 2017007097 A MX2017007097 A MX 2017007097A MX 2017007097 A MX2017007097 A MX 2017007097A MX 2017007097 A MX2017007097 A MX 2017007097A MX 2017007097 A MX2017007097 A MX 2017007097A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- combination
- myeloma
- treat cancer
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a regímenes de dosificación terapéuticos y combinaciones de los mismos para uso en el mejoramiento de la eficacia terapéutica de anticuerpos anti-CS1 en combinación con un anticuerpo de anti-Muerte Programada-1 (PD-1).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462087489P | 2014-12-04 | 2014-12-04 | |
PCT/US2015/063585 WO2016090070A1 (en) | 2014-12-04 | 2015-12-03 | Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma) |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017007097A true MX2017007097A (es) | 2017-09-05 |
Family
ID=55022696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017007097A MX2017007097A (es) | 2014-12-04 | 2015-12-03 | Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma). |
Country Status (13)
Country | Link |
---|---|
US (1) | US20170355768A1 (es) |
EP (1) | EP3227335A1 (es) |
JP (1) | JP2017537927A (es) |
KR (1) | KR20170088984A (es) |
CN (1) | CN107249632A (es) |
AU (1) | AU2015358462A1 (es) |
BR (1) | BR112017011538A2 (es) |
CA (1) | CA2969665A1 (es) |
EA (1) | EA201791049A1 (es) |
IL (1) | IL252535A0 (es) |
MX (1) | MX2017007097A (es) |
SG (1) | SG11201704343SA (es) |
WO (1) | WO2016090070A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR084309A1 (es) | 2010-12-17 | 2013-05-08 | Novartis Ag | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina |
EP3508500A1 (en) | 2011-04-29 | 2019-07-10 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
PL3081576T3 (pl) | 2013-12-12 | 2020-03-31 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne |
MX2018000621A (es) | 2015-07-13 | 2018-05-11 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos. |
JP2019534292A (ja) * | 2016-11-02 | 2019-11-28 | アペクシジェン, インコーポレイテッド | 組み合わせた抗cd40抗体および使用方法 |
WO2019200462A1 (en) * | 2018-04-16 | 2019-10-24 | Adaerata, Limited Partnership | Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド | 免疫療法のctla−4結合ペプチド |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
MXPA01006422A (es) | 1998-12-23 | 2002-06-04 | Pfizer Inc Abgenix Inc | Anticuerpos monoclonales humanos de ctla-4. |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
CZ301498B6 (cs) | 1999-02-22 | 2010-03-24 | Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) | C-21 modifikované epothilony |
BR0013581A (pt) | 1999-08-23 | 2002-07-02 | Dana Faber Cancer Inst Inc | Pd-1, um receptor para b7-4, e usos para isto |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
MXPA02001911A (es) | 1999-08-24 | 2003-07-21 | Medarex Inc | Anticuerpos ctla-4 humanos y sus usos. |
US7034121B2 (en) | 2000-01-27 | 2006-04-25 | Genetics Institue, Llc | Antibodies against CTLA4 |
US7041499B2 (en) | 2001-12-12 | 2006-05-09 | University Of North Texas Health Science Center | Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth |
PT3284753T (pt) | 2002-10-17 | 2020-05-04 | Genmab As | Anticorpos monoclonais humanos contra cd20 para utilização no tratamento da esclerose múltipla |
ATE514713T1 (de) | 2002-12-23 | 2011-07-15 | Wyeth Llc | Antikörper gegen pd-1 und ihre verwendung |
US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
US6958115B2 (en) | 2003-06-24 | 2005-10-25 | The United States Of America As Represented By The Secretary Of The Navy | Low temperature refining and formation of refractory metals |
DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
CA3201163A1 (en) | 2005-07-01 | 2007-01-11 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
WO2008019379A2 (en) | 2006-08-07 | 2008-02-14 | Pdl Biopharma, Inc. | Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells |
CA2660102C (en) | 2006-08-07 | 2017-02-21 | Pdl Biopharma, Inc. | Compositions and methods using anti-cs1 antibodies to treat multiple myeloma |
ES2589302T3 (es) * | 2006-08-07 | 2016-11-11 | Abbvie Biotherapeutics Inc. | Métodos de tratamiento de mieloma múltiple utilizando terapias de combinación basadas en HuLuc63 con bortezemib |
ES2616355T3 (es) | 2007-06-18 | 2017-06-12 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor humano de muerte programada PD-1 |
WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
JP2012507555A (ja) * | 2008-10-31 | 2012-03-29 | アボット バイオセラピューティクス コーポレイション | 稀少疾患の治療における抗cs1抗体の使用 |
US20130058921A1 (en) | 2009-10-30 | 2013-03-07 | Frits VAN RHEE | Use of autologous effector cells and antibodies for treatment of multiple myeloma |
EP2493485A1 (en) | 2009-10-30 | 2012-09-05 | University Of Arkansas For Medical Science | Use of autologous effector cells for treatment of multiple myeloma |
RU2625034C2 (ru) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Антитела и другие молекулы, которые связывают в7-н1 и pd-1 |
SG10201700698WA (en) * | 2012-05-15 | 2017-02-27 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
-
2015
- 2015-12-03 BR BR112017011538A patent/BR112017011538A2/pt not_active IP Right Cessation
- 2015-12-03 EA EA201791049A patent/EA201791049A1/ru unknown
- 2015-12-03 KR KR1020177017909A patent/KR20170088984A/ko unknown
- 2015-12-03 EP EP15816310.5A patent/EP3227335A1/en not_active Withdrawn
- 2015-12-03 JP JP2017529805A patent/JP2017537927A/ja not_active Withdrawn
- 2015-12-03 MX MX2017007097A patent/MX2017007097A/es unknown
- 2015-12-03 CA CA2969665A patent/CA2969665A1/en not_active Abandoned
- 2015-12-03 CN CN201580065674.2A patent/CN107249632A/zh active Pending
- 2015-12-03 WO PCT/US2015/063585 patent/WO2016090070A1/en active Application Filing
- 2015-12-03 US US15/531,538 patent/US20170355768A1/en not_active Abandoned
- 2015-12-03 SG SG11201704343SA patent/SG11201704343SA/en unknown
- 2015-12-03 AU AU2015358462A patent/AU2015358462A1/en not_active Abandoned
-
2017
- 2017-05-25 IL IL252535A patent/IL252535A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG11201704343SA (en) | 2017-06-29 |
WO2016090070A1 (en) | 2016-06-09 |
KR20170088984A (ko) | 2017-08-02 |
CN107249632A (zh) | 2017-10-13 |
BR112017011538A2 (pt) | 2018-03-13 |
IL252535A0 (en) | 2017-07-31 |
JP2017537927A (ja) | 2017-12-21 |
EP3227335A1 (en) | 2017-10-11 |
EA201791049A1 (ru) | 2017-10-31 |
US20170355768A1 (en) | 2017-12-14 |
AU2015358462A1 (en) | 2017-07-27 |
CA2969665A1 (en) | 2016-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500711A1 (en) | Anti-pd1 antibodies and methods of use | |
MY192999A (en) | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists | |
GEP20217331B (en) | Anti-tigit antibodies | |
MY195110A (en) | Antibodies to PD-1 and uses Thereof | |
PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
MX2018003936A (es) | Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones. | |
NZ738008A (en) | Tigit-binding agents and uses thereof | |
EA201691376A1 (ru) | Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака | |
PH12017500322A1 (en) | Anti-her2 antibodies and immunoconjugates | |
PH12016501894B1 (en) | Anti-ox40 antibodies and methods of use | |
MX2017004526A (es) | Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos. | |
PH12016501411B1 (en) | Bifunctional cytotoxic agents | |
PH12019500923A1 (en) | Anti-pd-1 antibodies and compositions | |
GEP20227343B (en) | Anti-lag3 antibodies and antigen-binding fragments | |
EA201790569A1 (ru) | Антитела и иммуноконъюгаты против cll-1 | |
NZ766356A (en) | Anti-pd-1 antibodies | |
MX2016015181A (es) | Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer. | |
MX2017004715A (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos. | |
MX2017007097A (es) | Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma). | |
MX2018010295A (es) | Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos. | |
GEP20217317B (en) | Combination therapy for the treatment of cancer | |
MA40612A (fr) | Nouveaux anticorps anti-mfi2 et méthodes d'utilisation | |
MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
MX2019003755A (es) | Regimen de dosificacion de avelumab para el tratamiento de cancer. | |
MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. |